CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.
There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.
This report aims to provide a comprehensive presentation of the global market for Chemotherapy Induced Peripheral Neuropathy Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chemotherapy Induced Peripheral Neuropathy Treatment. This report contains market size and forecasts of Chemotherapy Induced Peripheral Neuropathy Treatment in global, including the following market information:
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Chemotherapy Induced Peripheral Neuropathy Treatment companies in 2022 (%)
The global Chemotherapy Induced Peripheral Neuropathy Treatment market was valued at US$ 1723.6 million in 2022 and is projected to reach US$ 2613.1 million by 2029, at a CAGR of 6.1% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Americas is the largest market with about 47% market share. Europe is follower, accounting for about 27% market share.
The key players are Aptinyx Inc, Asahi Kasei Pharma Corp, Regenacy Pharmaceuticals, MAKScientific LLC, Metys Pharmaceuticals AG, Nemus Bioscience Inc, PledPharma, Sova Pharmaceuticals Inc, DermaXon LLC, Kineta Inc, Krenitsky Pharmaceuticals Inc, PeriphaGen, Apexian Pharma, WinSanTor etc.
We surveyed the Chemotherapy Induced Peripheral Neuropathy Treatment manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segment Percentages, by Type, 2022 (%)
Calcium Channel ?2-delta Ligands
Antidepressants
Opioids
Others
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segment Percentages, by Application, 2022 (%)
Platinum Agents
Taxanes
Vinca Alkaloids
Others
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Chemotherapy Induced Peripheral Neuropathy Treatment revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Chemotherapy Induced Peripheral Neuropathy Treatment revenues share in global market, 2022 (%)
Key companies Chemotherapy Induced Peripheral Neuropathy Treatment sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Chemotherapy Induced Peripheral Neuropathy Treatment sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Aptinyx Inc
Asahi Kasei Pharma Corp
Regenacy Pharmaceuticals
MAKScientific LLC
Metys Pharmaceuticals AG
Nemus Bioscience Inc
PledPharma
Sova Pharmaceuticals Inc
DermaXon LLC
Kineta Inc
Krenitsky Pharmaceuticals Inc
PeriphaGen
Apexian Pharma
WinSanTor
Outline of Major Chapters:
Chapter 1: Introduces the definition of Chemotherapy Induced Peripheral Neuropathy Treatment, market overview.
Chapter 2: Global Chemotherapy Induced Peripheral Neuropathy Treatment market size in revenue and volume.
Chapter 3: Detailed analysis of Chemotherapy Induced Peripheral Neuropathy Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Chemotherapy Induced Peripheral Neuropathy Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Chemotherapy Induced Peripheral Neuropathy Treatment capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Overall Market Size
2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size: 2022 VS 2029
2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales: 2018-2029
3 Company Landscape
3.1 Top Chemotherapy Induced Peripheral Neuropathy Treatment Players in Global Market
3.2 Top Global Chemotherapy Induced Peripheral Neuropathy Treatment Companies Ranked by Revenue
3.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Companies
3.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Companies
3.5 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Chemotherapy Induced Peripheral Neuropathy Treatment Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Product Type
3.8 Tier 1, Tier 2 and Tier 3 Chemotherapy Induced Peripheral Neuropathy Treatment Players in Global Market
3.8.1 List of Global Tier 1 Chemotherapy Induced Peripheral Neuropathy Treatment Companies
3.8.2 List of Global Tier 2 and Tier 3 Chemotherapy Induced Peripheral Neuropathy Treatment Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Markets, 2022 & 2029
4.1.2 Calcium Channel ?2-delta Ligands
4.1.3 Antidepressants
4.1.4 Opioids
4.1.5 Others
4.2 By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue & Forecasts
4.2.1 By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, 2018-2023
4.2.2 By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, 2024-2029
4.2.3 By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share, 2018-2029
4.3 By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales & Forecasts
4.3.1 By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales, 2018-2023
4.3.2 By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales, 2024-2029
4.3.3 By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share, 2018-2029
4.4 By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2022 & 2029
5.1.2 Platinum Agents
5.1.3 Taxanes
5.1.4 Vinca Alkaloids
5.1.5 Others
5.2 By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue & Forecasts
5.2.1 By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, 2018-2023
5.2.2 By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, 2024-2029
5.2.3 By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share, 2018-2029
5.3 By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales & Forecasts
5.3.1 By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales, 2018-2023
5.3.2 By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales, 2024-2029
5.3.3 By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share, 2018-2029
5.4 By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2022 & 2029
6.2 By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue & Forecasts
6.2.1 By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, 2018-2023
6.2.2 By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, 2024-2029
6.2.3 By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share, 2018-2029
6.3 By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales & Forecasts
6.3.1 By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales, 2018-2023
6.3.2 By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales, 2024-2029
6.3.3 By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, 2018-2029
6.4.2 By Country - North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales, 2018-2029
6.4.3 US Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2018-2029
6.4.4 Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2018-2029
6.4.5 Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, 2018-2029
6.5.2 By Country - Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales, 2018-2029
6.5.3 Germany Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2018-2029
6.5.4 France Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2018-2029
6.5.5 U.K. Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2018-2029
6.5.6 Italy Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2018-2029
6.5.7 Russia Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2018-2029
6.5.8 Nordic Countries Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2018-2029
6.5.9 Benelux Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, 2018-2029
6.6.2 By Region - Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales, 2018-2029
6.6.3 China Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2018-2029
6.6.4 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2018-2029
6.6.5 South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2018-2029
6.6.6 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2018-2029
6.6.7 India Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, 2018-2029
6.7.2 By Country - South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales, 2018-2029
6.7.3 Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2018-2029
6.7.4 Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales, 2018-2029
6.8.3 Turkey Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2018-2029
6.8.4 Israel Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2018-2029
6.8.5 Saudi Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2018-2029
6.8.6 UAE Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Aptinyx Inc
7.1.1 Aptinyx Inc Company Summary
7.1.2 Aptinyx Inc Business Overview
7.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings
7.1.4 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2018-2023)
7.1.5 Aptinyx Inc Key News & Latest Developments
7.2 Asahi Kasei Pharma Corp
7.2.1 Asahi Kasei Pharma Corp Company Summary
7.2.2 Asahi Kasei Pharma Corp Business Overview
7.2.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings
7.2.4 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2018-2023)
7.2.5 Asahi Kasei Pharma Corp Key News & Latest Developments
7.3 Regenacy Pharmaceuticals
7.3.1 Regenacy Pharmaceuticals Company Summary
7.3.2 Regenacy Pharmaceuticals Business Overview
7.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings
7.3.4 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2018-2023)
7.3.5 Regenacy Pharmaceuticals Key News & Latest Developments
7.4 MAKScientific LLC
7.4.1 MAKScientific LLC Company Summary
7.4.2 MAKScientific LLC Business Overview
7.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings
7.4.4 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2018-2023)
7.4.5 MAKScientific LLC Key News & Latest Developments
7.5 Metys Pharmaceuticals AG
7.5.1 Metys Pharmaceuticals AG Company Summary
7.5.2 Metys Pharmaceuticals AG Business Overview
7.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings
7.5.4 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2018-2023)
7.5.5 Metys Pharmaceuticals AG Key News & Latest Developments
7.6 Nemus Bioscience Inc
7.6.1 Nemus Bioscience Inc Company Summary
7.6.2 Nemus Bioscience Inc Business Overview
7.6.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings
7.6.4 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2018-2023)
7.6.5 Nemus Bioscience Inc Key News & Latest Developments
7.7 PledPharma
7.7.1 PledPharma Company Summary
7.7.2 PledPharma Business Overview
7.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings
7.7.4 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2018-2023)
7.7.5 PledPharma Key News & Latest Developments
7.8 Sova Pharmaceuticals Inc
7.8.1 Sova Pharmaceuticals Inc Company Summary
7.8.2 Sova Pharmaceuticals Inc Business Overview
7.8.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings
7.8.4 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2018-2023)
7.8.5 Sova Pharmaceuticals Inc Key News & Latest Developments
7.9 DermaXon LLC
7.9.1 DermaXon LLC Company Summary
7.9.2 DermaXon LLC Business Overview
7.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings
7.9.4 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2018-2023)
7.9.5 DermaXon LLC Key News & Latest Developments
7.10 Kineta Inc
7.10.1 Kineta Inc Company Summary
7.10.2 Kineta Inc Business Overview
7.10.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings
7.10.4 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2018-2023)
7.10.5 Kineta Inc Key News & Latest Developments
7.11 Krenitsky Pharmaceuticals Inc
7.11.1 Krenitsky Pharmaceuticals Inc Company Summary
7.11.2 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Business Overview
7.11.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings
7.11.4 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2018-2023)
7.11.5 Krenitsky Pharmaceuticals Inc Key News & Latest Developments
7.12 PeriphaGen
7.12.1 PeriphaGen Company Summary
7.12.2 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Business Overview
7.12.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings
7.12.4 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2018-2023)
7.12.5 PeriphaGen Key News & Latest Developments
7.13 Apexian Pharma
7.13.1 Apexian Pharma Company Summary
7.13.2 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Business Overview
7.13.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings
7.13.4 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2018-2023)
7.13.5 Apexian Pharma Key News & Latest Developments
7.14 WinSanTor
7.14.1 WinSanTor Company Summary
7.14.2 WinSanTor Business Overview
7.14.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings
7.14.4 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2018-2023)
7.14.5 WinSanTor Key News & Latest Developments
8 Global Chemotherapy Induced Peripheral Neuropathy Treatment Production Capacity, Analysis
8.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Production Capacity, 2018-2029
8.2 Chemotherapy Induced Peripheral Neuropathy Treatment Production Capacity of Key Manufacturers in Global Market
8.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Chemotherapy Induced Peripheral Neuropathy Treatment Supply Chain Analysis
10.1 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Value Chain
10.2 Chemotherapy Induced Peripheral Neuropathy Treatment Upstream Market
10.3 Chemotherapy Induced Peripheral Neuropathy Treatment Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Chemotherapy Induced Peripheral Neuropathy Treatment Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Chemotherapy Induced Peripheral Neuropathy Treatment in Global Market
Table 2. Top Chemotherapy Induced Peripheral Neuropathy Treatment Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Companies, 2018-2023
Table 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Companies, (K Units), 2018-2023
Table 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Product Type
Table 9. List of Global Tier 1 Chemotherapy Induced Peripheral Neuropathy Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Chemotherapy Induced Peripheral Neuropathy Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), 2018-2023
Table 15. By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), 2024-2029
Table 16. By Application ? Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), 2018-2023
Table 20. By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), 2024-2029
Table 21. By Region ? Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), 2018-2023
Table 25. By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), 2024-2029
Table 26. By Country - North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales, (K Units), 2018-2023
Table 29. By Country - North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales, (K Units), 2024-2029
Table 30. By Country - Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales, (K Units), 2018-2023
Table 33. By Country - Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales, (K Units), 2024-2029
Table 34. By Region - Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales, (K Units), 2018-2023
Table 37. By Region - Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales, (K Units), 2024-2029
Table 38. By Country - South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales, (K Units), 2018-2023
Table 41. By Country - South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales, (K Units), 2024-2029
Table 46. Aptinyx Inc Company Summary
Table 47. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 48. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. Aptinyx Inc Key News & Latest Developments
Table 50. Asahi Kasei Pharma Corp Company Summary
Table 51. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 52. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. Asahi Kasei Pharma Corp Key News & Latest Developments
Table 54. Regenacy Pharmaceuticals Company Summary
Table 55. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 56. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. Regenacy Pharmaceuticals Key News & Latest Developments
Table 58. MAKScientific LLC Company Summary
Table 59. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 60. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. MAKScientific LLC Key News & Latest Developments
Table 62. Metys Pharmaceuticals AG Company Summary
Table 63. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 64. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. Metys Pharmaceuticals AG Key News & Latest Developments
Table 66. Nemus Bioscience Inc Company Summary
Table 67. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 68. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. Nemus Bioscience Inc Key News & Latest Developments
Table 70. PledPharma Company Summary
Table 71. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 72. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. PledPharma Key News & Latest Developments
Table 74. Sova Pharmaceuticals Inc Company Summary
Table 75. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 76. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 77. Sova Pharmaceuticals Inc Key News & Latest Developments
Table 78. DermaXon LLC Company Summary
Table 79. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 80. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 81. DermaXon LLC Key News & Latest Developments
Table 82. Kineta Inc Company Summary
Table 83. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 84. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 85. Kineta Inc Key News & Latest Developments
Table 86. Krenitsky Pharmaceuticals Inc Company Summary
Table 87. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 88. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 89. Krenitsky Pharmaceuticals Inc Key News & Latest Developments
Table 90. PeriphaGen Company Summary
Table 91. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 92. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 93. PeriphaGen Key News & Latest Developments
Table 94. Apexian Pharma Company Summary
Table 95. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 96. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 97. Apexian Pharma Key News & Latest Developments
Table 98. WinSanTor Company Summary
Table 99. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 100. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 101. WinSanTor Key News & Latest Developments
Table 102. Chemotherapy Induced Peripheral Neuropathy Treatment Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 103. Global Chemotherapy Induced Peripheral Neuropathy Treatment Capacity Market Share of Key Manufacturers, 2021-2023
Table 104. Global Chemotherapy Induced Peripheral Neuropathy Treatment Production by Region, 2018-2023 (K Units)
Table 105. Global Chemotherapy Induced Peripheral Neuropathy Treatment Production by Region, 2024-2029 (K Units)
Table 106. Chemotherapy Induced Peripheral Neuropathy Treatment Market Opportunities & Trends in Global Market
Table 107. Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers in Global Market
Table 108. Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints in Global Market
Table 109. Chemotherapy Induced Peripheral Neuropathy Treatment Raw Materials
Table 110. Chemotherapy Induced Peripheral Neuropathy Treatment Raw Materials Suppliers in Global Market
Table 111. Typical Chemotherapy Induced Peripheral Neuropathy Treatment Downstream
Table 112. Chemotherapy Induced Peripheral Neuropathy Treatment Downstream Clients in Global Market
Table 113. Chemotherapy Induced Peripheral Neuropathy Treatment Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Type in 2022
Figure 2. Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Application in 2022
Figure 3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, 2018-2029 (US$, Mn)
Figure 7. Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Chemotherapy Induced Peripheral Neuropathy Treatment Revenue in 2022
Figure 9. By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share, 2018-2029
Figure 11. By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share, 2018-2029
Figure 12. By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (US$/Unit), 2018-2029
Figure 13. By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share, 2018-2029
Figure 15. By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share, 2018-2029
Figure 16. By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (US$/Unit), 2018-2029
Figure 17. By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share, 2018-2029
Figure 20. By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share, 2018-2029
Figure 21. By Country - North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share, 2018-2029
Figure 22. By Country - North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share, 2018-2029
Figure 23. US Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share, 2018-2029
Figure 28. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2029
Figure 29. France Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share, 2018-2029
Figure 37. China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2029
Figure 41. India Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share, 2018-2029
Figure 43. By Country - South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share, 2018-2029
Figure 44. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share, 2018-2029
Figure 48. Turkey Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$, Mn), 2018-2029
Figure 52. Global Chemotherapy Induced Peripheral Neuropathy Treatment Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Chemotherapy Induced Peripheral Neuropathy Treatment by Region, 2022 VS 2029
Figure 54. Chemotherapy Induced Peripheral Neuropathy Treatment Industry Value Chain
Figure 55. Marketing Channels
